TY - JOUR
T1 - Carrageenan-stimulated release of arachidonic acid and of lactate dehydrogenase from rat pleural cells
AU - Lo, Theresa N.
AU - Saul, Wilford F.
AU - Lau, Serrine S.
N1 - Funding Information:
Chemical Pharmacology, National Heart, Lung, and Blood Institute, and *Laboratory Therapeutics and Metabolism, Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, U.S.A.
PY - 1987/7/15
Y1 - 1987/7/15
N2 - Cells isolated from the rat pleural cavity consist mainly of macrophages, mast cells, eosinophils, and lymphocytes. Isolated pleural cells labeled with [14C]arachidonic acid released appreciable amounts (∼12%) of radiolabel upon exposure to pharmacological concentrations of carrageenan (1-100(μg/ml). The release of radiolabel was decreased by an inhibitor of phospholipase A2 (p-bromophenacyl bromide) but not by an inhibitor of arachidonate cyclooxygenase (indomethacin). The released products were arachidonic acid and, to a much lesser extent, prostaglandin E2 and leukotriene C4. The release of radiolabel was associated with release of cytosolic lactate dehydrogenase over the same range of carrageenan concentrations. Time-course studies indicated that release of radiolabel preceded that of lactate dehydrogenase. Since p-bromophenacyl bromide blocked stimulated release of radiolabel but did not prevent release of lactate dehydrogenase, it is unlikely that increase in arachidonate causes carrageenan-induced cell damage. Nevertheless, the question of whether the activation of phospholipase A2 in the pleural cells, most probably the macrophages, was sufficient to initiate the carrageenan-induced inflammatory response requires further study. Cytotoxicity which was apparent with as little as 5 μg/ml of carrageenan, may have been a significant consequence of carrageenan action.
AB - Cells isolated from the rat pleural cavity consist mainly of macrophages, mast cells, eosinophils, and lymphocytes. Isolated pleural cells labeled with [14C]arachidonic acid released appreciable amounts (∼12%) of radiolabel upon exposure to pharmacological concentrations of carrageenan (1-100(μg/ml). The release of radiolabel was decreased by an inhibitor of phospholipase A2 (p-bromophenacyl bromide) but not by an inhibitor of arachidonate cyclooxygenase (indomethacin). The released products were arachidonic acid and, to a much lesser extent, prostaglandin E2 and leukotriene C4. The release of radiolabel was associated with release of cytosolic lactate dehydrogenase over the same range of carrageenan concentrations. Time-course studies indicated that release of radiolabel preceded that of lactate dehydrogenase. Since p-bromophenacyl bromide blocked stimulated release of radiolabel but did not prevent release of lactate dehydrogenase, it is unlikely that increase in arachidonate causes carrageenan-induced cell damage. Nevertheless, the question of whether the activation of phospholipase A2 in the pleural cells, most probably the macrophages, was sufficient to initiate the carrageenan-induced inflammatory response requires further study. Cytotoxicity which was apparent with as little as 5 μg/ml of carrageenan, may have been a significant consequence of carrageenan action.
UR - http://www.scopus.com/inward/record.url?scp=0023204168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023204168&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(87)90610-1
DO - 10.1016/0006-2952(87)90610-1
M3 - Article
C2 - 3111482
AN - SCOPUS:0023204168
SN - 0006-2952
VL - 36
SP - 2405
EP - 2413
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 14
ER -